DF-006 is under clinical development by Drug Farm and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DF-006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DF-006 overview
DF-006 is under development for the treatment of Hepatitis B virus (HBV) infection and hepatocellular cancer. It is administered through oral route. The drug candidate acts by targeting alpha-protein kinase 1 (ALPK1) and is being developed based on IDInvivo technology.
Drug Farm overview
Drug Farm developing innovative treatments targeting the innate immunity for hepatitis B, cancer, and autoimmune diseases. It is headquartered in Shanghai, China.
For a complete picture of DF-006’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.